Identificador persistente para citar o vincular este elemento:
https://accedacris.ulpgc.es/handle/10553/139757
| Título: | Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs | Autores/as: | Stuckey, Ruth Navarrete Bullon, Laura Borrero Borrego, Asuncion Ballester, Violeta Vidal Rodriguez-Medina, Carlos Morales Curbelo, Alejandro Gonzalez Pinedo, Leslie Torres Ochando, Melissa Veiga Vaz, Alvaro Perera, Maria del Mar Bilbao Sieyro, Cristina López Rodríguez, Juan Francisco Segura Díaz, Adrian Gómez Casares, María Teresa |
Clasificación UNESCO: | 32 Ciencias médicas 3209 Farmacología 320708 Hematología |
Palabras clave: | Asciminib Tyrosine Kinase Inhibitors (Tkis) Cytopenia Subtherapeutic Dosing |
Fecha de publicación: | 2025 | Publicación seriada: | Annals of Hematology | Resumen: | This case highlights a young CML patient who achieved a major molecular response (MMR) after just four months with a subtherapeutic dose of asciminib. The patient could not tolerate full-dose asciminib, or the full dose of two previous tyrosine kinase inhibitors (TKI) due to myelotoxicity, but blood counts recovered rapidly upon TKI suspension and reduced dosing enabled sustained treatment. This is the second reported case of the use of 20 mg QD asciminib, four times below the recommended dose, and the first to demonstrate efficacy at this dose. The study emphasizes asciminib's potential for overcoming treatment challenges associated with multi-resistant/intolerant CML patients. | URI: | https://accedacris.ulpgc.es/handle/10553/139757 | ISSN: | 0939-5555 | DOI: | 10.1007/s00277-025-06339-5 | Fuente: | Annals Of Hematology[ISSN 0939-5555], v. 104, pp. 3007-3009 (Abril 2025) |
| Colección: | Artículos |
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.